YD Bio Limited Warrants(YDESW)Earnings, Financials & Key Ratios
YDESW•NASDAQ
$0.49
·Price updated May 6, 2026
AboutYD Bio Ltd. engages in the development of detection and therapeutic technologies. It offers cancer detection products, regenerative ophthalmology products, and exosome science. The company was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.Show more
- Revenue$510K+45.8%
- EBITDA-$1M-18252.9%
- Net Income-$1M-10509.7%
- EPS (Diluted)0.00
- Gross Margin30.44%-30.5%
- EBITDA Margin-265.93%-12490.7%
- Operating Margin-286.45%-10085.3%
- Net Margin-276.58%-7241.6%
- ROE-42.69%-172.4%
- ROIC-63.31%
- Debt/Equity0.00-99.8%
- Interest Coverage-1893.69-41131.6%
YDESW Key Insights
YD Bio Limited Warrants (YDESW) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
YDESW Price & Volume
YD Bio Limited Warrants (YDESW) stock price & volume — 10-year historical chart
Loading chart...
YDESW Growth Metrics
YD Bio Limited Warrants (YDESW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-43.48%
5 Years-43.48%
3 Years-43.48%
Last Year-44.14%
YDESW Peer Comparison
YD Bio Limited Warrants (YDESW) competitors in Diagnostics and Omics Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BNTX | 23.94B | 95.26 | -18.00 | 0.2% | -39.6% | -6.03% | 0.01 | |
 NVAX | 1.53B | 9.36 | 3.69 | 64.69% | -14.73% | |||
 OCGN | 492.54M | 1.46 | -6.33 | 8.83% | -15.37% | -26.26% | ||
 VXRT | 179.17M | 0.75 | 10.64 | 7.27% | 6.88% | 33.83% | 0.10 | |
 INO | 581.39M | 1.24 | -0.69 | -100% | -14.06% | 0.39 | ||
 DVAX | 1.82B | 15.50 | 77.50 | 19.36% | -13.13% | -8.13% | 0.43 | |
 NUVB | 1.75B | 5.04 | -8.40 | 6.99% | -102.06% | -44.1% | 0.03 | |
 SIGA | 336.57M | 4.70 | 14.24 | -31.8% | 24.64% | 0% | 0 |
Compare YDESW vs Peers
YD Bio Limited Warrants (YDESW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
YDESW Income Statement
YD Bio Limited Warrants (YDESW) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'23 | Dec'24 | TTM |
|---|---|---|---|
| Sales/Revenue | 350.13K | 510.36K | - |
| Revenue Growth % | - | 45.76% | - |
| Cost of Goods Sold | 196.69K | 355K | - |
| COGS % of Revenue | 56.17% | 69.56% | - |
| Gross Profit | 153.44K▲ 0% | 155.36K▲ 1.2% | -▲ 0% |
| Gross Margin % | 43.82% | 30.44% | - |
| Gross Profit Growth % | - | 1.25% | - |
| Operating Expenses | 163.29K | 1.62M | - |
| OpEx % of Revenue | 46.64% | 316.89% | - |
| Selling, General & Admin | 160.56K | 1.13M | - |
| SG&A % of Revenue | 45.86% | 220.71% | - |
| Research & Development | 0 | 491.35K | - |
| R&D % of Revenue | - | 96.28% | - |
| Other Operating Expenses | 2.73K | -493 | - |
| Operating Income | -9.85K▲ 0% | -1.46M▼ 14746.5% | -▲ 0% |
| Operating Margin % | -2.81% | -286.45% | - |
| Operating Income Growth % | - | -14746.45% | - |
| EBITDA | -7.39K | -1.36M | - |
| EBITDA Margin % | -2.11% | -265.93% | - |
| EBITDA Growth % | - | -18252.87% | - |
| D&A (Non-Cash Add-back) | 2.45K | 104.73K | - |
| EBIT | 19.79K | -1.39M | - |
| Net Interest Income | -1.85K | 11.04K | - |
| Interest Income | 290 | 11.81K | - |
| Interest Expense | 2.14K | 772 | - |
| Other Income/Expense | 27.5K | 75.45K | - |
| Pretax Income | 17.65K▲ 0% | -1.39M▼ 7955.4% | -▲ 0% |
| Pretax Margin % | 5.04% | -271.67% | - |
| Income Tax | 4.09K | 25.08K | - |
| Effective Tax Rate % | 23.17% | -1.81% | - |
| Net Income | 13.56K▲ 0% | -1.41M▼ 10509.7% | -▲ 0% |
| Net Margin % | 3.87% | -276.58% | - |
| Net Income Growth % | - | -10509.73% | - |
| Net Income (Continuing) | 13.56K | -1.41M | - |
| Discontinued Operations | 0 | 0 | - |
| Minority Interest | 0 | 0 | - |
| EPS (Diluted) | 0.00▲ 0% | 0.00▲ 0% | -▲ 0% |
| EPS Growth % | - | - | - |
| EPS (Basic) | 0.00 | 0.00 | - |
| Diluted Shares Outstanding | 0 | 0 | 0 |
| Basic Shares Outstanding | 0 | 0 | 0 |
| Dividend Payout Ratio | - | - | - |
YDESW Balance Sheet
YD Bio Limited Warrants (YDESW) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'23 | Dec'24 | TTM |
|---|---|---|---|
| Total Current Assets | 271.72K | 3.47M | - |
| Cash & Short-Term Investments | 87.1K | 3.13M | 3.13M |
| Cash Only | 87.1K | 3.13M | 3.13M |
| Short-Term Investments | 0 | 0 | - |
| Accounts Receivable | 98.43K | 262.8K | - |
| Days Sales Outstanding | 102.61 | 187.95 | - |
| Inventory | 69.4K | 37.34K | - |
| Days Inventory Outstanding | 128.8 | 38.39 | - |
| Other Current Assets | 0 | 0 | - |
| Total Non-Current Assets | 49.49K | 3.4M | - |
| Property, Plant & Equipment | 14.3K | 88.08K | - |
| Fixed Asset Turnover | 24.48x | 5.79x | - |
| Goodwill | 0 | 0 | - |
| Intangible Assets | 0 | 2.68M | - |
| Long-Term Investments | 10.62K | 0 | - |
| Other Non-Current Assets | 0 | 628.23K | - |
| Total Assets | 321.21K▲ 0% | 6.86M▲ 2037.0% | 6.86M▲ 0% |
| Asset Turnover | 1.09x | 0.07x | - |
| Asset Growth % | - | 2036.98% | - |
| Total Current Liabilities | 298.22K | 263.06K | - |
| Accounts Payable | 17.98K | 26.74K | - |
| Days Payables Outstanding | 33.36 | 27.5 | - |
| Short-Term Debt | 34.32K | 290 | - |
| Deferred Revenue (Current) | 0 | 0 | - |
| Other Current Liabilities | 344 | 0 | - |
| Current Ratio | 0.91x | 13.18x | 13.18x |
| Quick Ratio | 0.68x | 13.04x | 13.04x |
| Cash Conversion Cycle | 198.05 | 198.84 | - |
| Total Non-Current Liabilities | 0 | 10.92K | - |
| Long-Term Debt | 0 | 0 | - |
| Capital Lease Obligations | 0 | 5.68K | - |
| Deferred Tax Liabilities | 0 | 1.46K | - |
| Other Non-Current Liabilities | 0 | 3.77K | - |
| Total Liabilities | 298.22K | 273.98K | - |
| Total Debt | 47.58K | 22.55K | 22.55K |
| Net Debt | -39.52K | -3.11M | -3.11M |
| Debt / Equity | 2.07x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - |
| Net Debt / EBITDA | - | - | - |
| Interest Coverage | -4.59x | -1893.69x | - |
| Total Equity | 22.99K▲ 0% | 6.59M▲ 28560.7% | 6.59M▲ 0% |
| Equity Growth % | - | 28560.72% | - |
| Book Value per Share | - | - | - |
| Total Shareholders' Equity | 22.99K | 6.59M | 6.59M |
| Common Stock | 105.2K | 144.18K | - |
| Retained Earnings | -515.48K | -1.93M | - |
| Treasury Stock | 0 | 0 | - |
| Accumulated OCI | 47.21K | 45.07K | - |
| Minority Interest | 0 | 0 | - |
YDESW Cash Flow Statement
YD Bio Limited Warrants (YDESW) cash flow — operating, investing & free cash flow history
| Line item | Dec'23 | Dec'24 | TTM |
|---|---|---|---|
| Cash from Operations | -55.66K | -1.84M | -1.84M |
| Operating CF Margin % | -15.9% | -359.91% | - |
| Operating CF Growth % | - | -3200.25% | - |
| Net Income | 13.56K | -1.41M | - |
| Depreciation & Amortization | 2.45K | 104.73K | - |
| Stock-Based Compensation | 0 | 0 | - |
| Deferred Taxes | 4.09K | 26.58K | - |
| Other Non-Cash Items | 50.94K | 11.24K | - |
| Working Capital Changes | -126.7K | -567.81K | - |
| Change in Receivables | -63.86K | -11.02K | - |
| Change in Inventory | -30.57K | 28.52K | - |
| Change in Payables | 5.39K | 10.2K | - |
| Cash from Investing | -290 | -2.9M | - |
| Capital Expenditures | -290 | -74.91K | - |
| CapEx % of Revenue | 0.08% | 14.68% | - |
| Acquisitions | 0 | 0 | - |
| Investments | - | - | - |
| Other Investing | 0 | -2.84M | - |
| Cash from Financing | 113.89K | 7.73M | - |
| Debt Issued (Net) | -32.61K | -32.98K | - |
| Equity Issued (Net) | 52.95K | 1000K | - |
| Dividends Paid | 0 | 0 | - |
| Share Repurchases | 0 | 0 | - |
| Other Financing | 93.54K | -99.56K | - |
| Net Change in Cash | 56.96K▲ 0% | 3.05M▲ 5246.6% | -▲ 0% |
| Free Cash Flow | -55.95K▲ 0% | -4.75M▼ 8386.3% | -▲ 0% |
| FCF Margin % | -15.98% | -930.29% | - |
| FCF Growth % | - | -8386.27% | - |
| FCF per Share | - | - | - |
| FCF Conversion (FCF/Net Income) | -4.10x | 1.30x | - |
| Interest Paid | 2.14K | 772 | - |
| Taxes Paid | 0 | 0 | - |
YDESW Key Ratios
YD Bio Limited Warrants (YDESW) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2024 | TTM |
|---|---|---|
| Return on Equity (ROE) | -42.69% | - |
| Return on Invested Capital (ROIC) | -63.31% | -63.31% |
| Gross Margin | 30.44% | - |
| Net Margin | -276.58% | - |
| Debt / Equity | 0.00x | 0.00x |
| Interest Coverage | -1893.69x | - |
| FCF Conversion | 1.30x | - |
| Revenue Growth | 45.76% | - |
YDESW Frequently Asked Questions
YD Bio Limited Warrants (YDESW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
YD Bio Limited Warrants (YDESW) reported $0.5M in revenue for fiscal year 2024. This represents a 46% increase from $0.4M in 2023.
YD Bio Limited Warrants (YDESW) grew revenue by 45.8% over the past year. This is strong growth.
YD Bio Limited Warrants (YDESW) reported a net loss of $1.4M for fiscal year 2024.
Dividend & Returns
YD Bio Limited Warrants (YDESW) has a return on equity (ROE) of -42.7%. Negative ROE indicates the company is unprofitable.
YD Bio Limited Warrants (YDESW) had negative free cash flow of $4.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More YDESW
YD Bio Limited Warrants (YDESW) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates